Twenty-million patients each year undergo an MRI or MRA scan where they are injected with gadolinium-based contrast agents, otherwise known as GBCAs. In most of these patients, they expel the injected GBCA after the scan. This is accomplished through normal kidney function and urination. However, recent studies have shown many patients are unable to expel the GBCA, and instead retain toxic levels of gadolinium in their brain, bones and organ tissue, causing a wide variety of on-going symptoms.
Originally, the medical community believed that only patients with impaired renal/kidney function may have trouble purging their systems of the injected gadolinium.
However, research demonstrates, clearly, that toxic retention can happen to patients with healthy kidneys.
Simply put, it can happen to anyone.
Patients with toxic retention are said to have Gadolinium Deposition Disease (GDD). Certain patients might be at higher risk for GDD. These include:
- Anyone who has undergone multiple doses,
- Pregnant patients
- Pediatric patients,
- And patients with inflammatory conditions.
The FDA announced the decision to require additional warnings for GBCAs informing and warning patients about a potential risk for gadolinium retention.
This decision comes after a gadolinium hearing where various experts and patients discussed retention in the human body, including in organs and the brain. Affected patients spoke about the side effects of the drug retention in their body.
Gadolinium remains in several organs for months or years. The highest concentrations have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver, and spleen).
New Drug Warning by Manufacturer
As of May 2018, the makers of GCBA’s released and distributed an Important Drug Warning alerting and warning health care providers about the updated prescribing information for gadolinium. This updated information now is included in the Warnings and Precautions, Adverse Reactions, Pregnancy, Clinical Pharmacology and Patient Counseling sections. Specifically, the warnings detail the potential for gadolinium retention, especially in the bone and organs.
The highest retention is seen with linear rather than macrocyclic GBCAs; more simply, the organization of the molecules.
“Consequences of gadolinium retention in the brain have not been established,” the warning notes. “Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function.”
According to the warning, patients with normal renal function have shown pathologic skin changes among other side effects.
The order of highest to lowest retention of GBCAs:
- Lastly ProHance
Health care providers must advise patients that the drug can remain in the brain, bones, or other organs of patients with normal renal function for months or years.
GBCAs injected in patients undergoing an MRI to enhance the image created. Evidence exists that gadolinium does not leave the body as quickly as the drug manufacturers promised, if at all. Instead, it remains in various parts of the body, putting the patient at risk of exposure to excess gadolinium.
Gadolinium Deposition Disease
Gadolinium deposition disease (GDD) occurs when a person has normal or adequate renal function but develops persistent and/or painful symptoms ranging anywhere from a few hours to several weeks after injection of a gadolinium contrast agent.
Several medical conditions, including the following:
- Gadolinium storage condition
- Gadolinium deposition disease (GDD)
- Nephrogenic systemic fibrosis (NSF)
Those symptoms of having gadolinium poisoning include:
- Brain fog
- Bone pain
- Pain in the arms and legs
- Tissue burning
Symptoms Associated with GDD
The symptoms linked with retention are diverse, varied and plentiful. Some of the most commonly reported symptoms include:
- Brain fog
- Burning, cutting or sharp pains in a patient’s arms, legs or torso
- Changes in color lesions, thickening, and tightness, etc. of your skin
- Chronic headaches
- Cognitive impairment
- Deep bone and joint pains
- Feelings of sharp pins and needles
- Hair Loss
- Itching skin
- Muscle twitches or severe weakness
- Nausea and/or vomiting
- Severe degradation of vision and dry eyes
- Tingling and/or prickling pains
- Trouble with swallowing
- Trouble speaking (weakening of voice)
In September 2017, the U.S. Food and Drug Administration (FDA) voted 13-1 (with one abstention) to add a warning about the risk of retention after use of GBCAs.
Toxicity Class Action
Most people believe that when a lot of individuals are injured by a single product or medicine that the victims would find a law firm to file a class action lawsuit.
When you contact Lerner and Rowe Injury Attorneys with your case, you can trust that each plaintiff’s case is handled and resolved on its own merits through Mass Tort Litigation, not class action.
In October 2016, the first gadolinium deposition disease lawsuit was filed against the maker of a gadolinium-based contrast agent; alleging patients did not receive proper warning about the risks associated with gadolinium retention. Since that time, victims filed several lawsuits, living across the country in both state and federal courts.
Suffering from GDD? Contact Lerner and Rowe Injury Attorneys immediately to discuss your options. Our toxicity attorneys will answer your questions and will fight to protect your rights. We answer our phone 24/7 and, also, have a LiveChat option available online.
Lerner and Rowe GDD Class Action Attorneys
Lerner and Rowe Injury Attorneys is one of the largest personal injury law firms in the country; with offices located in Oregon, Washington, California, Nevada, Arizona, New Mexico, Louisiana, Tennessee, Illinois, and Indiana. Our attorneys know how to fight against large corporate pharmaceutical giants; we can also handle personal injury cases and class action medical and product liability class action claims! So, don’t wait and contact us today.